patent

Poltreg will receive a patent in China that covers the administration of its cell-based therapy PTG-007 for multiple sclerosis (MS) via an injection into the spinal canal, or intrathecally. The method showed superior benefits compared with PTG-007’s intravenous infusion into the bloodstream in a Phase 1b/2a study of people…

The U.S. Patent and Trademark Office (USPTO) has notified Vanda Pharmaceuticals that it will grant a new patent covering the use of Ponvory (ponesimod), an approved oral treatment for relapsing forms of multiple sclerosis (MS), that will span nearly two decades, the company announced. The upcoming patent specifically…

LAPIX Therapeutics has secured a new U.S. patent covering the use of its experimental oral therapy LPX-TI641 as a means to restore immune tolerance in people with autoimmune diseases such as multiple sclerosis (MS). Issued by the U.S. Patent and Trademark Office with the number 11,648,225, the patent…

Biogen has secured a new patent in Europe covering the use of its oral therapy Tecfidera (dimethyl fumarate) for multiple sclerosis (MS) through 2028, the company announced. Granted by the European Patent Office, patent EP2653873 covers the composition and use of dimethyl fumarate at a dose of 480…

Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, “…

A decision by the U.S. Court of Appeals for the Federal Circuit has upheld the validity of a patent for dosing Novartis’ oral multiple sclerosis (MS) treatment Gilenya (fingolimod), the medication’s manufacturer announced. “With this decision, Novartis confirms that it expects no generic versions of Gilenya in the…

New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa…

In the past year, BrainStorm Cell Therapeutics was granted four patents and is waiting for a fifth, already accepted, meant to provide protection for its NurOwn cell therapy and technology in territories around the world. NurOwn is being tested in clinical trials as a potential treatment for…

Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…

Tonix Pharmaceuticals has filed a patent application with the World Intellectual Property Organization covering the use of TNX-1500 — its third-generation anti-CD154 antibody — for the prevention and treatment of autoimmune diseases, such as multiple sclerosis (MS), and organ transplant rejection. “There remains a significant need for new treatments with improved…

SomaCeuticals, a subsidiary of AngioSoma, has acquired exclusive global rights to a patented formula that aims to ease and possibly eliminate signs of neurodegeneration in people with multiple sclerosis (MS). By entering a licensing agreement with 7 to Stand, a Delaware corporation, SomaCeuticals gained access…

Therapeutics Solutions International has announced filing a new patent covering the memory protective effects of its natural nutritional supplement QuadraMune, as seen in an animal model of memory loss caused by inflammation. QuadraMune is a nutritional supplement, available in capsule form, made of four ingredients with known anti-inflammatory, neuroprotective, and…

Generic formulations of dimethyl fumarate — currently sold as Tecfidera by Biogen — were given a green light to enter the U.S. market, after a federal court invalidated a patent protecting Tecfidera from generic competition as a multiple sclerosis (MS) treatment.  The ruling by the District Court for the…

The United States Patent and Trademark Office has issued a patent covering the intellectual rights to MedRhythms’ proprietary audio engine, a core component of the company’s rhythmic sound products designed to improve the walking ability of adult patients with multiple sclerosis (MS) and other neurological disorders. The…

The United States Patent and Trademark Office (USPTO) has issued a patent to Endonovo Therapeutics for Application No. 15/549,748, which covers the company’s technique and device for electromagnetic treatment of multiple sclerosis (MS). Endonovo has a pipeline of “Electroceuticals” — wearable, electronic, non-invasive therapeutic devices. These devices…

Anavex Life Sciences has received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of several neurodegenerative and neurodevelopmental conditions, including multiple sclerosis (MS) and Rett syndrome. Issued by the U.S. Patent and Trademark Office, the new patent (no. 10,507,196) covers…

MetP Pharma‘s patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS), has been approved by the United States Patent and Trademark Office (USPTO). The patent, titled “Treatment of Demyelinating Diseases” (U.S. Appl. No. 16/506,830), is valid until 2039,…

Axim Biotech announced that its way of extracting and purifying THC (delta-9-tetrahydrocannabinol) — an active compound in medical cannabis — has been approved to receive a patent. The notice of allowance for patient No. 15/146668 came in letter from the United States Patent and Trademark Office (USPTO), Axim said in…

The United States and Australia have issued patents on Sonde Health‘s voice-analysis technology for diagnosing and monitoring multiple sclerosis and other diseases that affect speech. Sonde, which has dubbed its invention vocal biomarker technology, said the U.S. patent is  9,936,914 and the Australian one 2014374349. Both patents cover Sonde’s…

MMJ International Holdings is seeking a patent for a part-cannabinoid and part-non-cannabinoid treatment for multiple sclerosis and other diseases. The company said in a news release that it filed the patent request ahead of Phase 2 clinical trials of the formulation.  The therapy was developed by MMJ Bioscience, an affiliate of MMJ International…

MMJ International Holdings has applied to the U.S. Patent and Trademark Office (USPTO) for new pharmaceutical compounds and methods to treat and prevent symptoms associated with multiple sclerosis (MS) and other diseases responsive to cannabinoids. The patent covers MMJ BioScience’s intellectual property portfolio, which comprises several patent families…

RedHill Biopharma has received a Notice of Allowance for a new patent on RHB-104 its potential therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Once granted by the United States Patent and Trademark Office (USPTO), this patent will be valid until 2032. RHB-104 is a proprietary, orally-administered antibiotic combination with potentially potent intracellular, antimycobacterial…

The U.S. Patent and Trademark Office has issued a patent for human embryonic stem cells derived mesenchymal stem cells, called hES-T-MSC or T-MSC, and for their method of production. This newly patented technology was developed by ImStem Biotechnology in collaboration with the University of Connecticut (UConn) to advance new…

A European Patent Office decision has opened the door to Synthon providing cheaper generic versions of Teva Pharmaceutical’s Copaxone to people with relapsing multiple sclerosis. What looks like the final hurdle to the generics was cleared when the patent office’s Technical Board of Appeal revoked the last of the patents that Teva…

A ruling by the  U.S. District Court for the District of Delaware invalidated four of five patents held by Acorda Therapeutics that pertained to Ampyra (dalfampridine), a treatment for walking difficulties in multiple sclerosis (MS) patients, raising the possibility of generic forms of the drug coming onto the market in a…

The United States has granted a patent to Kadimastem’s stem cell-based technology for treating multiple sclerosis (MS) and other diseases of the nervous system. The patent involves the technology the company used to produce supporting cells in the central nervous system derived from human stem cells, including myelin-producing cells. The United…

AXIM Biotechnologies announced that the United States Patent and Trademark Office (USPTO) will be issuing a patent covering all cannabinoids — both natural and synthetic —  used in a chewing gum delivery system that may be included in its cannabinoid-containing, controlled-release chewing gum products. The USPTO has given the company a Notice of…

Columbia Care announced the launch of its line of pills for medical marijuana — calling it the first controlled-dose, pharmaceutical-quality and solid-fill medical cannabinoid capsule available to people with prescriptions for medical marijuana use in the U.S. The New York State Department of Health recently approved the capsule line, in…

RegeneRx Biopharmaceuticals announced that it has received an Intent to Grant notice from the European Patent Office (EPO) regarding a patent for its proprietary molecule Thymosin beta 4 (Tβ4), a potential therapy for multiple sclerosis (MS) designed to promote remyelination. The patent will cover the use of Tβ4 in a composition for treating or reducing…

The European Patent Office has released a Notice of Intention to Grant a new patent to support RHB-104 as a therapy for relapsing-remitting multiple sclerosis (RRMS). RHB-104 is being developed  by RedHill Biopharma. Patents covering the use of RHB-104 exist in over 25 countries, including the U.S., Australia, Canada, Japan, and in…